Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Cutler, Corey S  [Clear All Filters]
2022
Zaiken MC, Flynn R, Paz KG, Rhee SY, Jin S, Mohamed FA, Saha A, Thangavelu G, Park PMC, Hemming ML, et al. BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022.
Shapiro RM, Birch GC, Hu G, Cadavid JVergara, Nikiforow S, Baginska J, Ali AK, Tarannum M, Sheffer M, Abdulhamid YZ, et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for post-transplant relapse. J Clin Invest. 2022.
Gooptu M, Kim HT, Jacobsen ED, Fisher DC, Lacasce AS, Ho VT, Cutler CS, Koreth J, Soiffer RJ, Antin JH, et al. Favorable Outcomes Following Allogeneic Transplantation in Adults with Hemophagocytic Lymphohistiocytosis. Blood Adv. 2022.
Whangbo J, Nikiforow S, Kim HT, Wahl J, Reynolds CG, Rai SChamling, Kim S, Burden AThomas, Alho A, Lacerda JF, et al. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Blood Adv. 2022.
2021
Ho VT, Kim HT, Brock J, Galinsky I, Daley H, Reynolds CG, Weber A, Pozdnyakova O, Severgnini M, Nikiforow S, et al. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized double blinded phase 2 trial. Blood Adv. 2021.
2020
Divito SJ, Aasebo AT, Matos TR, Hsieh P-C, Collin M, Elco CP, O'Malley JT, Bækkevold ES, Reims HM, Gedde-Dahl T, et al. Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host-disease. J Clin Invest. 2020.
Gowin K, Ballen K, Ahn KWoo, Hu Z-H, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973.
2019
Gooptu M, Kim HT, Howard A, Choi SW, Soiffer RJ, Antin JH, Ritz J, Cutler CS. Effect of sirolimus on immune reconstitution following myeloablative allogeneic stem-cell transplantation: An ancillary analysis of a randomized controlled trial comparing Tacrolimus/Sirolimus with Tacrolimus/Methotrexate (Blood and Marrow Transplant Clin. Biol Blood Marrow Transplant. 2019.
2016
Deol A, Sengsayadeth S, Ahn KWoo, Wang H-L, Aljurf M, Antin JHarry, Battiwalla M, Bornhäuser M, Cahn J-Y, Camitta B, et al. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016.
Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani AR, Alyea EP, Carlton VE, Bin Chen Y-, Cutler CS, et al. Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016.
McDonald-Hyman C, Flynn R, Panoskaltsis-Mortari A, Peterson N, MacDonald KPA, Hill GR, Luznik L, Serody JS, Murphy WJ, Maillard I, et al. Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5 dependent manner. Blood. 2016.
2015
DePalo J, Chai X, Lee SJ, Cutler CS, Treister N. Assessing the relationship between oral chronic graft-versus-host disease and global measures of quality of life. Oral Oncol. 2015.
El-Jawahri A, Li S, Antin JH, Spitzer TR, Armand PA, Koreth J, Nikiforow S, Ballen KK, Ho VT, Alyea EP, et al. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in The Modern Years. Biol Blood Marrow Transplant. 2015.
2014
Arora M, Hemmer MT, Ahn KWoo, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RPeter, Inamoto Y, et al. CIBMTR Chronic GVHD Risk Score Predicts Mortality in an Independent Validation Cohort. Biol Blood Marrow Transplant. 2014.
2013
Saber W, Cutler CS, Nakamura R, Zhang M-J, Atallah E, J Rizzo D, Maziarz RT, Cortes J, Kalaycio ME, Horowitz MM. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood. 2013.